The KLB rs12152703 variant confers protection against hepatic inflammation in patients with MASLD by boosting Klotho-beta expression

This study highlights the protective effect of a genetic variant in the Klotho-beta (<i>KLB</i>) gene in attenuating hepatic inflammation and disease severity in both adults and children with metabolic dysfunction-associated steatotic liver disease. The favorable clinical associations appear to be mediated by increased circulating and hepatic KLB protein levels. Consistently, KLB overexpression alleviates lipid overload in hepatocytes by modulating the expression of genes involved in lipid metabolism. Together, these findings support the FGF19/KLB axis as a promising therapeutic target for the treatment of severe metabolic dysfunction-associated steatotic liver disease.

Authors

Institutions

Publication Details

Journal
JHEP Reports
Published
2025-12-23
DOI
https://doi.org/10.1016/j.jhepr.2025.101717
Primary Topic
Parathyroid Disorders and Treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The KLB rs12152703 variant confers protection against hepatic inflammation in patients with MASLD by boosting Klotho-beta expression

Francesca Tiano, Valentina Doria, Anna Ludovica Fracanzani, Antonella Mosca et al.
JHEP Reports
Parathyroid Disorders and Treatments
article

The KLB rs12152703 variant confers protection against hepatic inflammation in patients with MASLD by boosting Klotho-beta expression

Francesca Tiano, Valentina Doria, Anna Ludovica Fracanzani, Antonella Mosca, C. De Stefanis, Paola Dongiovanni, Marica Meroni, Miriam Longo, Marco Maggioni, Erika Paolini, Sara Badiali, Nadia Panera, Ettore Mosca, Anna Alisi
article en

Abstract

This study highlights the protective effect of a genetic variant in the Klotho-beta (<i>KLB</i>) gene in attenuating hepatic inflammation and disease severity in both adults and children with metabolic dysfunction-associated steatotic liver disease. The favorable clinical associations appear to be mediated by increased circulating and hepatic KLB protein levels. Consistently, KLB overexpression alleviates lipid overload in hepatocytes by modulating the expression of genes involved in lipid metabolism. Together, these findings support the FGF19/KLB axis as a promising therapeutic target for the treatment of severe metabolic dysfunction-associated steatotic liver disease.

JHEP ReportsVol. 8(4)
University of Milan (IT), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), Bambino Gesù Children's Hospital (IT), Institute of Biomedical Technologies (IT), National Research Council (IT)
Ospedale Pediatrico Bambino Gesù, Ministero della Salute
Good health and well-being
Openalex Percentile: Top 32%
Parathyroid Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

The KLB rs12152703 variant confers protection against hepatic inflammation in patients with MASLD by boosting Klotho-beta expression — Francesca Tiano, Valentina Doria, et al. · JHEP Reports (2025) | TGRS Research Map | TGRS